BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 12393618)

  • 1. Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma.
    Tsimberidou AM; McLaughlin P; Younes A; Rodriguez MA; Hagemeister FB; Sarris A; Romaguera J; Hess M; Smith TL; Yang Y; Ayala A; Preti A; Lee MS; Cabanillas F
    Blood; 2002 Dec; 100(13):4351-7. PubMed ID: 12393618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective randomized study to compare the molecular response rates between central lymphatic irradiation and intensive alternating triple chemotherapy in the treatment of stage I-III follicular lymphoma.
    Ha CS; Cabanillas F; Lee MS; Tucker SL; McLaughlin P; Rodriguez MA; Younes A; Romaguera JE; Mesina OM; Cox JD
    Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):188-93. PubMed ID: 16111588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma.
    Luminari S; Marcheselli L; Sacchi S; Pozzi S; Bari A; Ilariucci F; Stelitano C; Angrilli F; Lazzaro A; Baldini L
    Cancer; 2009 May; 115(9):1906-13. PubMed ID: 19248044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternating triple therapy for the treatment of intermediate grade and immunoblastic lymphoma.
    Cabanillas F; Rodriguez-Diaz Pavón J; Hagemeister FB; McLaughlin P; Rodriguez MA; Romaguera JE; Dong K; Moon T
    Ann Oncol; 1998 May; 9(5):511-8. PubMed ID: 9653492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin- vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis.
    Velasquez WS; McLaughlin P; Fuller LM; Allen PK; Tucker SL; Swan F; Rodriguez MA; Hagemeister FB; Cabanillas FF
    Cancer; 1994 May; 73(9):2408-16. PubMed ID: 7513251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study.
    Nastoupil LJ; McLaughlin P; Feng L; Neelapu SS; Samaniego F; Hagemeister FB; Ayala A; Romaguera JE; Goy AH; Neal E; Wang M; Fayad L; Fanale MA; Oki Y; Westin JR; Rodriguez MA; Cabanillas F; Fowler NH
    Br J Haematol; 2017 Apr; 177(2):263-270. PubMed ID: 28340281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: high remission rates and reversion to negative of peripheral blood bcl-2 rearrangement.
    McLaughlin P; Hagemeister FB; Swan F; Cabanillas F; Romaguera J; Rodriguez MA; Lee MS; Pate O; Sarris A; Younes A
    Ann Oncol; 1994; 5 Suppl 2():73-7. PubMed ID: 7515650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of fludarabine/mitoxantrone/dexamethasone alternating with CHOP in bulky follicular non-Hodgkin's lymphoma.
    Wilder DD; Ogden JL; Jain VK
    Clin Lymphoma; 2002 Mar; 2(4):229-37. PubMed ID: 11970762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of granulocyte colony-stimulating factor in patients with diffuse large cell lymphoma treated with intensive chemotherapy.
    Avilés A; Díaz-Maqueo JC; Talavera A; Nambo MJ; García EL
    Leuk Lymphoma; 1994 Sep; 15(1-2):153-7. PubMed ID: 7532056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
    Luo SK; Li J; Hong WD; Zhao Y; Tong XZ
    Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of mitoxantrone in the treatment of indolent lymphomas.
    Hagemeister F; Cabanillas F; Coleman M; Gregory SA; Zinzani PL
    Oncologist; 2005 Feb; 10(2):150-9. PubMed ID: 15709217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacious but insidious: a retrospective analysis of fludarabine-induced myelotoxicity using long-term culture-initiating cells in 100 follicular lymphoma patients.
    Janikova A; Koristek Z; Vinklarkova J; Pavlik T; Sticha M; Navratil M; Kral Z; Vasova I; Mayer J
    Exp Hematol; 2009 Nov; 37(11):1266-73. PubMed ID: 19654036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO.
    Mainwaring PN; Cunningham D; Gregory W; Hoskin P; Hancock B; Norton AJ; MacLennan K; Smith P; Hudson GV; Linch D
    Blood; 2001 May; 97(10):2991-7. PubMed ID: 11342422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma.
    Hänel M; Kröger N; Kroschinsky F; Birkmann J; Hänel A; Herbst R; Naumann R; Friedrichsen K; Ehninger G; Zander AR; Fiedler F
    J Cancer Res Clin Oncol; 2001; 127(6):387-95. PubMed ID: 11414199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
    Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P
    Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas.
    Rohatgi N; LaRocca RV; Bard V; Sethuraman G; Foon KA
    Am J Hematol; 2002 Jul; 70(3):181-5. PubMed ID: 12111762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma.
    McLaughlin P; Hagemeister FB; Rodriguez MA; Sarris AH; Pate O; Younes A; Lee MS; Dang NH; Romaguera JE; Preti AH; McAda N; Cabanillas F
    Semin Oncol; 2000 Dec; 27(6 Suppl 12):37-41. PubMed ID: 11225999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-Hodgkin's lymphomas: a review of the M.D. Anderson experience.
    Cabanillas F
    Semin Oncol; 1992 Feb; 19(1 Suppl 1):11-3. PubMed ID: 1384134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha.
    McLaughlin P; Estey E; Glassman A; Romaguera J; Samaniego F; Ayala A; Hayes K; Maddox AM; Preti HA; Hagemeister FB
    Blood; 2005 Jun; 105(12):4573-5. PubMed ID: 15741224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.